LD-2 disclosure · 2nd Quarter - Report
GENENTECH
Client
- Name
- GENENTECH
- Location
- District of Columbia · United States of America
Registrant
- Description
- Government affairs.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesMedicare/Medicaid
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
LobbyistsSHANNON FINLEY · LUKE HATZIS · MARTIN B. GOLD · JOSEPH EANNELLO · JEFFREY CARROLL · mr CHARLES PATRICK MICHAELS
Covered position (mr CHARLES PATRICK MICHAELS): Chief of Staff, Deputy Chief of Staff, Legislative Director, Senior Legislative Assistant, and Legislative Assistant, Rep. David Schweikert; Staff Assistant, Rep. Ted Budd; Intern, Senator James DeMint.
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
340B Program issues and patient access to pharmaceuticals. Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains. Enhanced FDA reporting and risk mitigation plans for certain medicines. Incentives for antimicrobial and antiviral research, medical countermeasures, and novel product development.
LobbyistsSHANNON FINLEY · LUKE HATZIS · MARTIN B. GOLD · JOSEPH EANNELLO · JEFFREY CARROLL